<?xml version="1.0" encoding="UTF-8"?>
<ref id="B149-biomedicines-08-00060">
 <label>149.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Vidal</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Pandha</surname>
    <given-names>H.S.</given-names>
   </name>
   <name>
    <surname>Yap</surname>
    <given-names>T.A.</given-names>
   </name>
   <name>
    <surname>White</surname>
    <given-names>C.L.</given-names>
   </name>
   <name>
    <surname>Twigger</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Vile</surname>
    <given-names>R.G.</given-names>
   </name>
   <name>
    <surname>Melcher</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Coffey</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Harrington</surname>
    <given-names>K.J.</given-names>
   </name>
   <name>
    <surname>DeBono</surname>
    <given-names>J.S.</given-names>
   </name>
  </person-group>
  <article-title>A phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer</article-title>
  <source>Clin. Cancer Res.</source>
  <year>2008</year>
  <volume>14</volume>
  <fpage>7127</fpage>
  <lpage>7137</lpage>
  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0524</pub-id>
  <pub-id pub-id-type="pmid">18981012</pub-id>
 </element-citation>
</ref>
